Publications by authors named "Tim Wohlfarth"
Background: The purpose of this observational study was to evaluate feasibility, efficacy results and toxicity observations of capecitabine in routine first line treatment of patients with metastatic colorectal cancer, with particular regard of elderly patients (>75 years of age).
Methods: Patients with colorectal cancer receiving capecitabine as part of their first-line treatment were recorded until detection of disease progression or up to a maximum of 12 cycles on standardized evaluation forms. Additional information on long-term outcomes, progression-free survival, and overall survival were retrieved at two follow-up time points.
Background: In elderly patients with HER2-positive breast cancer, few data on efficacy and toxicity of adjuvant trastuzumab treatment exists since older patients were in general excluded from large randomized studies. This prospective observational study aimed to confirm the beneficial findings from pivotal trials in age cohorts ≥65 years.
Materials And Methods: There were no restrictions for recruitment with respect to age or concomitant/sequential adjuvant medication.
Article Synopsis
- This observational study aimed to assess the safety of capecitabine-based adjuvant therapy in patients with resected stage III colon cancer in a real-world clinical setting.
- A total of 1485 patients were observed, with the majority experiencing common side effects like hand-foot syndrome and diarrhea, while serious adverse events were relatively low (6.5%).
- The study highlighted that 77.9% of patients completed six or more treatment cycles, but it also recognized limitations, such as the lack of efficacy data and unvalidated questionnaires regarding patient expectations and satisfaction.
Aim: This non-interventional surveillance study (NIS) collected data on the quality of life (QoL) of patients treated with capecitabine as mono- or combination chemotherapy in an outpatient setting.
Methods: Capecitabine was administered orally for 14 days of each 21-day cycle. The main parameters of interest were QoL, compliance, patient and physician satisfaction, handling of hand-foot syndrome (HFS), and efficacy.
Background: Trastuzumab was registered in 2000 for the treatment of metastatic breast cancer, both as monotherapy and combination therapy with paclitaxel. In this prospective, non-interventional observation study, the 10-year experience with trastuzumab in the routine management of HER2-positive breast cancer was reviewed.
Methods: Between 2000 and 2010, 1843 evaluable patients with advanced HER2-positive breast cancer were recruited in 223 institutions across Germany.